Overview

Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects

Status:
Completed

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

- This is a single centre, phase I, randomized, double-blind, placebo-controlled, crossover, dose escalating study of P7435 using single and multiple doses, to be conducted in healthy male and female (Non child bearing) subjects having BMI between 19 to 40 kg/m2. - The study will be conducted in 2 parts as follows: Part A will consist of the Single Ascending Dose (SAD) study and Part B will consist of the Multiple Ascending Dose (MAD) study.

Phase:

Phase 1

Details

Lead Sponsor:

Piramal Enterprises Limited

Collaborator:

Profil Institute for Clinical Research, Inc.